U.S. markets closed

Genmab A/S (GNMSF)

Other OTC - Other OTC Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
276.47+3.66 (+1.34%)
Al cierre: 03:57PM EDT

Genmab A/S

Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com

Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 2,204

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO2.87MN/D1961
Mr. Anthony PaganoExecutive VP & CFO1.02MN/D1978
Ms. Birgitte Stephensen M.Sc.Executive VP & Chief Legal Officer632.27kN/D1961
Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer689.75kN/D1971
Mr. Martin SchultzSenior Director of Clinical Operations & Non-Independent Director114.96kN/D1976
Dr. Tahamtan AhmadiExecutive VP, Chief Medical Officer & Head of Experimental Medicines1.11MN/D1973
Dr. Mijke Zachariasse Ph.D.Senior Director, Head of Antibody Research Materials & Non-Independent Director158.07kN/D1974
Mr. Takahiro HamataniSenior Director of Finance Japan & Non-Independent Director114.96kN/D1975
Mr. Anthony ManciniExecutive VP & COO1.09MN/D1971
Mr. Andrew CarlsenSenior Director, VP & Head of Investor RelationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Gestión corporativa

La calificación ISS Governance QuickScore de Genmab A/S a partir del 1 de mayo de 2024 es 3. Las puntuaciones principales son Auditoría: 1; Junta: 1; Derechos del accionista: 1; Compensación: 9.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.